Isconova to develop human vaccines with animal technology
This article was originally published in Scrip
Isconova has secured SKK30 million ($5.0 million) to develop human vaccine adjuvants and increase vaccine production and marketing. The cash will help the Swedish firm diversify its pipeline which largely consists of marketed animal vaccines. The company's vaccine adjuvant technology, ISCOM, makes longer-lasting and more protective vaccines. The technology is already established in horse vaccines throughout Europe and Isconova will now explore ISCOM in humans. The investment was provided by InnovationsKapital and other undisclosed private investors.